Kantify at the CONDOR Symposium on Sarcoma

Soft tissue sarcomas and liposarcomas remain therapeutic blind spots. Despite decades of research, the pipeline of novel targets and effective small molecules is scarce, leaving clinicians with limited treatment options and patients with urgent unmet needs.

We are proud to participate in the CONDOR Symposium 2025 on the Microenvironment and Immunotherapy of Sarcomas, held in Bordeaux on September 25–26, 2025.

This high-level event convenes leading academic and industry experts to discuss breakthroughs in tumor immunology, novel therapeutic targets, and translational insights. CONDOR provides a platform to engage with the international sarcoma community and to highlight how AI can unlock new therapeutic strategies where conventional discovery has reached its limits.

CONDOR

The CONDOR consortium is a unique initiative enabled by the highly structured sarcoma care organization in France, the national sarcoma database, and the dynamism of the French Sarcoma Group. With unparalleled patient access and the world’s largest portfolio of sarcoma immunotherapy trials, CONDOR integrates biological resources, clinical expertise, and industry collaboration at scale. Its mission is to deliver four key outputs: (i) a comprehensive sarcoma immune atlas, (ii) a predictive digital pathology tool, (iii) a peripheral plasma-based signature to guide patient selection, and (iv) early-phase trials on novel targets. This combination positions CONDOR as the most advanced global effort to transform the treatment landscape of sarcomas.

Highlights of the event

The 2025 program brings together leading international experts to present advances across the spectrum of sarcoma research. Highlights include new insights into the immune microenvironment of sarcomas, translational data from the CONgRAtS trial of immune checkpoint combinations, and the unveiling of spatial transcriptomic maps that shed light on resistance mechanisms. Dedicated sessions will address the biology of dedifferentiated liposarcomas, angiosarcomas, and bone sarcomas, as well as the development of predictive biomarkers and novel immunotherapy approaches. This unique convergence of biology, clinical research, and translational innovation underscores why CONDOR has become the reference meeting in sarcoma immuno-oncology.

Kantify's work in soft tissue sarcoma

At Kantify, we are among the pioneers applying Artificial Intelligence to target discovery and small molecule design in sarcomas, with the conviction that AI can succeed where traditional approaches have stalled.

Our AI drug discovery platform, Sapian, explores vast chemical and biological landscapes to uncover hidden opportunities:

• Identifying novel targets in soft tissue sarcoma and liposarcoma.

• Designing first-in-class small molecules with optimized safety and efficacy profiles.

• Accelerating discovery timelines from years to weeks, without compromising scientific rigor.

Learn more about CONDOR on the CONDOR website